Imprivata Patient Privacy Intelligence vs Protenus (2026)
The two AI centrality leaders in privacy monitoring, and they disagree at the root about how to find a violation. Imprivata explains: it tries first to tie each access to a legitimate clinical reason, an appointment, an encounter, a diagnosis code, and flags only the residue it cannot account for, which is a claim about evidence rather than about the person and earns the best governance grade among the workforce surveillance vendors, backed by the only peer reviewed validation in the category. Protenus profiles: it builds behavioural profiles of patients and users and reasons about whether an access was appropriate, an approach graded C on governance for flagging named clinicians with no published fairness evaluation, but it does what Imprivata does not, covering diversion as well as privacy from one platform with Best in KLAS in both. Imprivata's evidence largely predates its FairWarning and Maize merger, a continuity question to press. If your failure mode is minimising false accusations, start with Imprivata. If your failure mode is covering privacy and diversion together, start with Protenus.
- A method that structurally avoids flagging people for being unusual, graded A on governance, the best among the workforce surveillance vendors indexed: it explains each access against a legitimate clinical reason and surfaces only the residue it cannot account for, a claim about evidence rather than about the person.
- The only peer reviewed academic validation of a core method in the category, graded A on evidence: the Explanation Based Auditing research reported explanations for over 94 percent of accesses against a real health system log, with the work cited more than 50 times, plus Best in KLAS in 2021.
- Data does not leave the organisation, graded A on deployment and PHI: the system runs in a virtual machine inside the customer environment, and the vendor tells customers to keep manual review running until they have validated it themselves, the most conservative oversight posture in the lane.
- Two risk domains from one platform: patient privacy monitoring and drug diversion surveillance share one engine, so a single purchase covers both the privacy office and the pharmacy, where Imprivata is privacy only.
- Independent validation in both domains, graded B on evidence: Best in KLAS in 2023 for both patient privacy monitoring and drug diversion surveillance, which Imprivata's privacy only scope cannot match on breadth.
- The clearest AI necessity case, graded A on AI centrality: 100 percent coverage of accesses and medication transactions in place of manual sampling, with the same platform trained differently for the two use cases, protected by granted patents.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Imprivata Patient Privacy Intelligence and Protenus are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Imprivata Patient Privacy Intelligence | Protenus |
|---|---|---|
| Primary category | Healthcare Cybersecurity | Healthcare Cybersecurity |
| Founded | Not recorded | 2014 |
| Headquarters | Waltham, Massachusetts, United States | Baltimore, Maryland, United States |
| Website | imprivata.com | protenus.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Imprivata Patient Privacy Intelligence its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Protenus, Imprivata Patient Privacy Intelligence grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Protenus its top capability grade on AI Centrality and EHR and Interoperability Depth. Set against Imprivata Patient Privacy Intelligence, Protenus grades higher on EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Imprivata Patient Privacy Intelligence or Protenus?
On the axes where the AI Health Index separates them, Imprivata Patient Privacy Intelligence grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Clinical and Operational Evidence, and Protenus grades higher on EHR and Interoperability Depth. Imprivata Patient Privacy Intelligence leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Imprivata Patient Privacy Intelligence and Protenus differ most?
The widest separation the AI Health Index records between Imprivata Patient Privacy Intelligence and Protenus is on AI Governance and Bias Disclosure, where Imprivata Patient Privacy Intelligence grades A and Protenus grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Imprivata Patient Privacy Intelligence and Protenus grade the same?
The AI Health Index grades Imprivata Patient Privacy Intelligence and Protenus the same on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Healthcare Administrative Automation page.
Both grade A on AI centrality, and the split is method against scope. The methods differ at the root, which drives the governance grades: Imprivata explains accesses, matching each against a legitimate reason and flagging only the unexplained residue, so it does not profile individuals and grades A on governance; Protenus profiles behaviour, building profiles of patients and users and reasoning about appropriateness, an approach graded C on governance because it flags named clinicians with no published fairness evaluation.
Protenus answers a need Imprivata does not, covering diversion as well as privacy from one platform, with Best in KLAS in both. Imprivata carries the stronger evidence and transparency on its single domain, graded A on both, but its peer reviewed record and its in customer deployment model largely predate the FairWarning and Maize merger into Patient Privacy Intelligence, so buyers should confirm which capabilities carried over. Both are consequential workforce surveillance tools. Neither publishes a security attestation or pricing.